Bliss GVS Pharma

₹624.20As of Sun 8 Nov 2026, 12:00 UTC

NSE:BLISSGVSHealthcare

Country India

PE (Fwd) 45.49

TSR 10Y CAGR 15.33%

Div yield 0.24%

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 1.20

PE TTM 52.01

TSR TTM 299.58%

Mkt cap ₹69.30B

ROIC —

SE Grade™

Value

Quality

Moat

—

1Y Price

Reference

₹693

11.07%

(86.15%)

Price above Reference Value

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

9.271

Revenue₹B

—

7.475

7.516

7.702

8.097

9.271

9.795

5.53%

14.50

Revenue growth%

—

0.55

2.48

5.13

14.50

5.66

3.80

—

51.70

Gross margin%

—

46.07

44.97

47.98

46.83

51.70

51.66

46.83

14.14

Operating margin%

—

13.55

13.13

16.13

12.07

14.14

14.13

13.55

13.93

Net margin%

—

2.01

9.43

9.80

10.41

13.93

14.16

9.80

52.01

P/E ratio (avg)x

—

72.40

11.50

16.70

17.19

14.76

48.42

16.70

51.23

EV/EBITx

—

10.75

8.258

10.14

14.83

14.53

48.54

10.75

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

12.00

EPS₹

—

1.43

6.72

7.11

7.95

12.00

12.89

70.21%

—

50.95

EPS growth%

—

369.89

5.89

11.76

50.95

7.41

31.36

—

Bookvalue per sh₹

—

FCF per share₹

—

1.50

Dividend per sh₹

—

0.50

1.50

1.67

31.61%

—

0.24

Div yield (avg)%

—

0.48

0.65

0.42

0.37

0.85

0.27

0.48

12.50

Payout ratio%

—

34.97

7.44

7.03

6.29

12.50

12.98

7.44

107.6

Shares (diluted)M

—

105.2

105.5

106.1

106.0

107.6

◌107.6

0.56%

(1.47)

Buyback yield%

—

(0.26)

(0.56)

0.04

(1.47)

◌—

(0.41)

—

D/E ratiox

—

67.16

Enterprise value₹B

—

10.89

8.146

12.60

14.49

19.05

67.16

15.01%

—

LT debt₹M

—

Peers (US$684.0M)

Cap (US$)

FDC Limited

676.6M

20.29x

Sun Pharma Advanced…

669.6M

3.849x

Innova Captab Limited

623.6M

38.02x

Shandong Wit Dyne…

686.4M

16.18x

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

10.92

12.04

Own earn%

—

Sh yield%

(1.23)

0.12

Owners

Insiders/Inst%

43.53

13.50

Short interest%

—

SBC / revenue%

0.93

Record

10Y

Profitable years

5/5

Revenue growth years

4/4

EPS growth years

4/4

Dividend streakyrs

Op margin range%

12–16

$1 testx

—

Incr. ROIC%

—

Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹9.271B

5.53%

1.00×

Cost of revenue

₹4.478B

2.67%

0.90×

Operating expenses

₹3.482B

9.40%

1.15×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m